Tanvex BioPharma USA, Inc. Achieves Dual U.S. Regulatory Milestones: FDA Approves Nypozi(TM) and FDA Accepts Biosimilar Biologics License Application for TX-05
FDA Approval of Nypozi™ and FDA BLA Acceptance of TX-05 Further Validates Tanvex’s Expertise in Biologics Development and Manufacturing. SAN DIEGO, CA / ACCESSWIRE / August 19, 2024 / Tanvex…
